See related research article by Kokkonen *et al*., <http://arthritis-research.com/content/9/3/R56>

After publication of our recent article \[[@B1]\], we noticed an error in Table 6 \'Relative risk for developing rheumatoid arthritis in patients, stratified for anti-cyclic citrullinated peptide (anti-CCP) antibodies\'.

Under the heading of \'Anti-CCP antibody-positive\', the first line should read \'HLA-shared epitope-negative\', and the second line should read \'HLA-shared epitope-positive\'. Similarly, under the heading \'Anti-CCP antibody-negative\', the first line should read \'HLA-shared epitope-negative\' and the second line should read \'HLA-shared epitope-positive\'.

The correct table is given here as Table [1](#T1){ref-type="table"} (a corrected version of Table 6 \[[@B1]\]).

###### 

Relative risk for developing rheumatoid arthritis in patients, stratified for anti-cyclic citrullinated peptide (anti-CCP) antibodies

                                 Nonsmoking   Smoking                      
  ------------------------------ ------------ ------------------- -------- --------------------
  Anti-CCP antibody-positive                                               
   HLA-shared epitope-negative   33/41        1.00                71/49    1.67 (0.95--2.94)
   HLA-shared epitope-positive   62/33        2.05 (1.12--3.75)   143/21   7.61 (4.05--14.30)
  Anti-CCP antibody-negative                                               
   HLA-shared epitope-negative   40/41        1.00                52/49    1.11 (0.63--1.95)
   HLA-shared epitope-positive   23/33        0.71 (0.37--1.38)   31/21    1.92 (0.98--3.77)

The combination of carriage of HLA-shared epitope alleles or not, and ever or never smoking were compared for groups stratified for anti-CCP antibodies.
